Age modifies recurrence risk across the 2025 American Thyroid Association risk stratification in papillary thyroid carcinoma
Journal of the Endocrine Society · 02.11.2026 · 10 (12)
DOI: 10.1210/jendso/bvag259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Endocrine Society, online erschienen am 12.11.2026. Verfasst von Li'nan Qin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgical Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy o…. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research, National Natural Science Foundation of China.
Abstract (Originalsprache)
Context
The 2025 American Thyroid Association (ATA) guidelines updated recurrence risk stratification for papillary thyroid cancer (PTC). Whether age modifies the absolute structural recurrence risk represented by these strata is unclear.
Objective
To determine whether age modifies 5-year structural recurrence risk across ATA 2025 stratification in PTC and improves risk prediction.
Methods
This retrospective cohort study included 14 397 patients with PTC who underwent initial surgery at a tertiary cancer center in China from 2000 to 2018. The primary outcome was 5-year structural recurrence-free survival. Cox models with restricted cubic splines evaluated age effects and ATA2025-by-age interaction. ATA-based and age-interaction models were compared by temporal validation and decision-curve analysis.
Results
The median age was 43.0 years, 10 867 patients (75.5%) were female, and 758 (5.3%) experienced structural recurrence during a median follow-up of 60.0 months. Observed 5-year risk rose from 1.7% to 12.5% across ATA2025 stratification. Age modified risk across stratifications (global interaction P < .001). After treatment adjustment, 5-year risk fell from 2.37% at age 35 years to 0.69% at age 65 years in the low-risk group but rose from 8.21% to 19.28% in the high-risk group. In temporal validation, the C-index was 0.745 for both models; 5-year areas under the curve were 0.743 and 0.747, and Brier scores were 0.043 and 0.042. Decision curves showed little overall difference.
Conclusion
Age identified meaningful heterogeneity in absolute structural recurrence risk, particularly in high-risk PTC, but added little to predictive performance or decision value. External validation is required before age is used to guide treatment or surveillance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Head and Neck Surgical Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, C…
ORCID-Profile: Li'nan Qin, Yunhe Liu, Xiwei Zhang, Jie Liu, Hui Huang
Förderung
- National High Level Hospital Clinical Research
- National Natural Science Foundation of China
Zitieren
APA
Qin, L., Liu, Y., Zhang, X., Yan, D., Liu, J., Liu, W., Ni, S., Huang, H., & Liu, S. (2026). Age modifies recurrence risk across the 2025 American Thyroid Association risk stratification in papillary thyroid carcinoma. Journal of the Endocrine Society, 10(12). https://doi.org/10.1210/jendso/bvag259
Vancouver
Qin L, Liu Y, Zhang X, Yan D, Liu J, Liu W, et al. Age modifies recurrence risk across the 2025 American Thyroid Association risk stratification in papillary thyroid carcinoma. Journal of the Endocrine Society. 2026;10(12). doi:10.1210/jendso/bvag259
BibTeX
@article{Qin2026,
author = {Qin, Li'nan and Liu, Yunhe and Zhang, Xiwei and Yan, Dangui and Liu, Jie and Liu, Wensheng and Ni, Song and Huang, Hui and Liu, Shaoyan},
title = {Age modifies recurrence risk across the 2025 American Thyroid Association risk stratification in papillary thyroid carcinoma},
journal = {Journal of the Endocrine Society},
year = {2026},
volume = {10},
number = {12},
doi = {10.1210/jendso/bvag259}
}
EUVIMED